GOPC-ROS1重排作为肺腺癌对奥希替尼获得性耐药机制及对克唑替尼联合治疗敏感的机制 - Suppr

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.

作者信息

Zeng Liang, Yang Nong, Zhang Yongchang

机构信息

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.

出版信息

J Thorac Oncol. 2018 Jul;13(7):e114-e116. doi: 10.1016/j.jtho.2018.02.005.

DOI:10.1016/j.jtho.2018.02.005

PMID:29935846

Abstract

摘要

相似文献

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.GOPC-ROS1重排作为肺腺癌对奥希替尼获得性耐药机制及对克唑替尼联合治疗敏感的机制

J Thorac Oncol. 2018 Jul;13(7):e114-e116. doi: 10.1016/j.jtho.2018.02.005.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.通过综合基于 mRNA 的酪氨酸激酶融合筛选鉴定肺腺癌中的 KIF5B-RET 和 GOPC-ROS1 融合。

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.液体活检检测到MET扩增且对EGFR酪氨酸激酶抑制产生继发性耐药的肺癌患者对克唑替尼和奥希替尼联合治疗的反应

J Thorac Oncol. 2018 Sep;13(9):e169-e172. doi: 10.1016/j.jtho.2018.04.007.

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.在一名接受厄洛替尼和奥希替尼治疗的肺腺癌患者的循环肿瘤DNA中检测到新型SPECC1L-MET融合基因。

J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160.

Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.吉非替尼联合克唑替尼对奥希替尼治疗失败的表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）耐药患者的疗效——通过新一代测序新发现STRN-ALK融合基因

J Thorac Oncol. 2019 Jul;14(7):e143-e144. doi: 10.1016/j.jtho.2019.02.014.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.克唑替尼治疗后 ROS1 基因重排反复复发的非小细胞肺癌患者的完全代谢缓解。

Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.克唑替尼对ROS1荧光原位杂交和免疫组化阳性肺腺癌的显著反应：病例系列

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24.

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.ROS1 重排非小细胞肺癌患者中不同类型 ROS1 融合伙伴的克唑替尼疗效。

J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.

First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.一线克唑替尼与铂类培美曲塞化疗用于晚期 ROS1 重排非小细胞肺癌患者。

Cancer Med. 2020 May;9(10):3310-3318. doi: 10.1002/cam4.2972. Epub 2020 Mar 13.

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.伴有继发性耐药突变的ROS1重排非小细胞肺癌：病例报告及当前观点

Clin Lung Cancer. 2019 Nov;20(6):e593-e596. doi: 10.1016/j.cllc.2019.06.007. Epub 2019 Jun 13.

引用本文的文献

Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges.第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药后的策略：机遇与挑战

Cancer Med. 2025 May;14(9):e70921. doi: 10.1002/cam4.70921.

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.优化奥希替尼用于非小细胞肺癌的治疗：靶向耐药性并探索联合疗法。

Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.

Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.依伐卡托是一种CFTR增强剂，通过调节CFTR-PTEN-AKT轴，与奥希替尼协同作用，对抗非小细胞肺癌对奥希替尼的获得性耐药。

Acta Pharmacol Sin. 2025 Apr;46(4):1045-1057. doi: 10.1038/s41401-024-01427-0. Epub 2024 Dec 3.

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.表皮生长因子受体（EGFR）突变型非小细胞肺癌不断变化的治疗格局。

Nat Rev Clin Oncol. 2025 Feb;22(2):95-116. doi: 10.1038/s41571-024-00971-2. Epub 2024 Nov 29.

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Routine Clinically Detected Increased Transcripts Are Related With Expression by Immunohistochemistry and Associated With Mutations in Lung Adenocarcinoma.常规临床检测到的转录本增加与免疫组织化学表达相关，并与肺腺癌中的突变有关。

JTO Clin Res Rep. 2023 May 24;4(7):100530. doi: 10.1016/j.jtocrr.2023.100530. eCollection 2023 Jul.

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择

Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。

J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。

Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.

Acquired Resistance to Osimertinib in -Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?奥希替尼耐药的 - 突变型非小细胞肺癌：我们如何克服它？

Int J Mol Sci. 2022 Jun 22;23(13):6936. doi: 10.3390/ijms23136936.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献